New drug discovery technologies are advancing therapies across various modalities, including molecular glues and protein degraders.
2
Cell therapies are expanding their applications to solid tumors and autoimmune diseases, showcasing significant potential.
3
Challenges remain in demonstrating value to investors in a capital-constrained environment within the industry.
4
The coexistence of different therapeutic modalities as part of a mixed ecosystem is a critical consideration for the field.
5
The Power List 2026 features 60 individuals recognized for their contributions, with 20 in each category: Small Molecules, Biopharma, and Advanced Medicines.
